People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Asher Biotherapeutics, Inc. | — | Biotechnology | Series D+ | $163.5M | $654.9M | 2021 |
| Synnovation Therapeutics, Inc. | — | Biotechnology | Series B | $52.0M | $136.3M | 2023 |
Reid Huber at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Reid Huber on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ian Clark | 1 | 5 |
| Elaine Sun | 1 | 3 |
| Jeffrey Tong | 1 | 2 |
| Craig Gibbs | 1 | 2 |
| Andy Yeung | 1 | 1 |
| Don O'Sullivan | 1 | 1 |
| Yik Andy Yeung | 1 | 1 |
| Liangxing Wu | 1 | 1 |
| Wenqing Yao | 1 | 1 |
| Ting Feng | 1 | 1 |
| Ivana Djuretic | 1 | 1 |
| Kyle Elrod | 1 | 1 |
| Bob Deresiewicz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.